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DNase I and MPE*Fe(II) footprinting both employ partial cleavage of
ligand-protected DNA restriction fragments and Maxam-Gilbert sequencing gel
methods of analysis. One method utilizes the enzyme, DNase I, as the DNA
cleaving agent while the other employs the synthetic molecule, methidium-
propyl-EDIA (MPE). For actinomycin D, chrcmcmycin A3 and distamycin A, DNase
I footprinting reports larger binding site sizes than MPE-Fe(II). DNase I
footprinting appears more sensitive for weakly bound sites. MPEFe(II)
footprinting appears more accurate in determining the actual size and location
of the binding sites for small molecules on DNA, especially in cases where
several small molecules are closely spaced on the DNA. MPE*Fe(II) and DNase I
report the same sequence and binding site size for J.= repressor protein on
operator DNA.
A rapid, direct method for determining the location and size of the
binding sites of proteins on heterogeneous DNA is DNase I footprinting, which
combines DNase I cleavage of protein-protected DNA fragments and Maxam-Gilbert
sequencing gel method of analysis.(1,2) This useful DNA cleavage inhibition
pattern technique relies on the relatively low sequence specificity of the
enzyme DNase I in a partial DNA cleavage reaction and the ability of the DNA
bound protein to prevent cleavage of the DNA backbone between the base pairs
it covers. The protein-protected DNA sequence is expressed as a gap in the
sequencing ladder seen in the autoradiogram of a Maxam-Gilbert sequencing gel
revealing the position and extent of the protein binding site.(l1,2)
Many small molecules, such as drugs useful in antibiotic, antiviral,
and antitumor chemotherapy bind double helical nucleic acid in a sequence
specific fashion at sites typically two to four base pairs in size.(3) Some
small molecules, such as bleomycin, chemically modify DNA which allows
identification of specific binding sites on heterogenous DNA from DNA cleavage
patterns on Maxam-Gilbert sequencing gels (4-6). However, many DNA binding
molecules do not modify nucleic acids and our understanding of their sequence
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preferences has been limited to camparison of binding isotherms obtained by
spectrophotometric analyses of drug binding to hanopolymer and copolymer
nucleic acids.(3) One direct method reported for determining the binding
sites of small molecules with binding site sizes in the range of three to four
base pairs on heterogeneous DNA is MPE*Fe(II) footprinting.(7-9)
Methidiumpropyl-EDTA (MPE), which contains the DNA intercalator,
methidium, covalently bound by a short hydrocarbon tether to the metal
chelator, EDTA, efficiently produces single strand breaks in double helical
DNA in the presence of Fe(II) and 02. (Figure 1) (10) Importantly, MPE*Fe(II)
is a relatively non-sequence specific DNA cleaving agent with lower sequence
specificity than DNase I.(7-9) Using MPE*Fe(II) footprinting, the binding
sites of actinomycin, netropsin, distamycin, chrcmomycin, mithramycin, and
olivomycin over a range of binding densities on some DNA restriction fragments
have been determined. (7-9) The DNA cleavage inhibition patterns (footprints)
on opposite strands are asymmetric, shifted at least one base pair to the 3'
side of the presumed drug binding site.(8,9)
Recently, DNase I has been shown capable of generating DNA cleavage
inhibition patterns with actinomycin and distamycin at very low binding
densities.(ll) The question arises whether MPE-Fe(II) and DNase I
footprinting report the same information. It is not obvious whether the
synthetic MPE-Fe(II) and the enzyme DNase I are equally sensitive to the same
phenomiena. They are comnon because they are both DNA cleaving reagents.
Hawever, they differ in size, mechanism of cleavage, and level of sequence
neutrality. We report here a oomparison between MPE-Fe(II) and DNase I
footprinting patterns generated on DNA fragments protected by actinomycin D,
chromomycin A3 and distamycin A. (Figure 2) Actinomycin and chromomycin bind
DNA preferentially at guanine rich sequences with binding site sizes of 3-5
base pairs.(7-9,13-21) Distamycin binds DNA preferentially at A+T rich
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Figure 1: Methidiumpropyl-EDTA.Fe(II).
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sequences with a binding site size of 4-5 base pairs.(7,8,22-24) DNase I
treatment of a DNA restriction fragment containing the I.Q operator sequence
protected by J.= repressor protein has been shown to afford a footprint 23
base pairs in size.(l) For camparison an MPE*Fe(II) footprint of the protein
J.= repressor on operator DNA is included.
MAIERIALS AND METlICS
Drugs: Actinomycin D was obtained from Merck, Sharp and Dohme.
Chramnmycin A3 was obtained fran Calbiochein. Distamycin A was obtained from
Boehringer Mannheim. MPE was synthesized and purified as described by
Hertzberg and Dervan.(10) Purities were determined by thin layer
chrcmatography. Concentrations were determined spectroscopically.
Prgteina: La= repressor, a gift fram R. E. Dickerson (UCLA), was
supplied as a 9.35 mg protein/ml solution in a K2PO4 (pH 7.4)/glucose buffer
and stored at -700C until immediately before use. Deoxyribonuclease 1 (DNase
I), isolated from bovine pancreas, was obtained from Worthington (code: DPFF).
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Figure 2: TLbp to Bottan: actincomycin, chrancoycin, distamycin.
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DNase I was prepared as a 1 mg/ml stock solution in 0.15 M NaCl, stored at
-200C and diluted to working concentrations immediately before use.
Restriction endonucleases and the Klenow fragment of DNA polymerase 1 were
fram New England Biolabs. Bacterial alkaline phosphatase and T4 kinase were
from Bethesda Research Laboratories.
Buffers: MPE cleavage reactions were done in a buffer (TN) containing
10 mM Tris, pH 7.4 and 50 mM NaCl. DNase I digestions were done in a buffer
(TKMC) containing 10 mM Tris pH 7.9, 10 mM KC1, 10 mM MgC12, and 5 mM CaC12.
DM Fr +-aects: A 381 base pair DNA restriction fragment was isolated
from pBR322. Superhelical pBR322 plasmids were first digested with the
restriction endonuclease Barn Hl and then 3' end labeled with a -32P dATP and
the Klenow fragment of DNA polymerase 1. Similarly, the Bam Hl restriction
fragment was treated with bacterial alkaline phosphatase and then 5' end
labeled with y-32P dATP and T4 kinase. A second enzymatic digest with the
restriction endonuclease Eco RI yielded either the 3' (or 5') end labeled 381
bp DNA fragment which was isolated and eluted fran polyacrylamide gels by
known procedures.(12) A 117 base pair DNA fragment containing a sequenced
segment of the lactose operon in E. coli was isolated fran the plasmid
pLJ3.(25) Superhelical pLJ3 plasmids were first digested with Eco RI, then 3'
end labeled with a-32P and the Klenow fragment of DNA polymerase 1. Digestion
of this material with Hae III yielded the singularly 3' end labeled 117 base
pair fragment used for 2a= repressor binding.
MPE} kFoprintina: To 8 pl of a solution containing 1.25 x TN buffer,
250 VM base pairs DNA (primarily deproteinized calf thymus with sufficient 3'
32p end-labeled fragment for autoradiography), and inhibiting drug (either
actinomycin D, chromamycin A3/MgC12, distamycin A; see figures 3 and 4 for
concentrations) was added 1 pl of a 100 pM MPE.200 1M Fe(NH4)2(SO4)2 solu-
tion. 'This was allowed to equilibrate at 370C for 30 mins. Addition of 1 11
of 40 mM dithiothreitol (DTT) initiated the cleavage reaction which was
allowed to continue at 370C for 15 min before stopping by freezing in dry ice.
Samples were then lyophilized and resuspended in a formamide loading buffer.
In the case of the 5' 32p end labeled fragment the final DNA concentration was
400 1M in base pairs. For the 2= repressor binding, the final DNA
concentration was 100 1aM base pairs and equilibration was at roam temperature
for 10 mins.
DNase I Footprintina: A 9 1l solution containing 1.11 x TKMC buffer,
222 1M base pairs DNA, and inhibiting drug is allowed to equilibrate for 30
mins at 370C. Cleavage is initiated by the addition of 1 pl of 50 Vg/ml DNase
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I and 1 mM DIT solution and allowed to react for 30 sec at room temperature
before quenching with 2.5 pl of a DNase stop solution (3 M NH4OAc and 0.25 M
EJY). Tlhis was then precipitated with ethanol, lyophilized, and resuspended
in a formamide loading buffer. For laa repressor binding, DIase I reactions
followed the conditions described by Galas and Schmitz.(l)
S= ncing Gels: Resolution of inhibition patterns was achieved by
electrophoresis on 0.4 mn thick, 40 an long, 8% polyacrylamide, 1:20
crosslinked sequencing gels containing 50% urea. Electrophoresis was carried
out at lOOOV for 3.5 hours to sequence 100 nucleotides, beginning 20
nucleotides fram the 3' (or 5') end-labeled end. Autoradiography was carried
out at -500C without the use of an intensification screen.
Densitometry: An 8xlO' copy of the original autoradiogram was scanned
at 485 nm with the incident beam collimated to a width of 0.2 mu on a Cary 219
spectrophotaneter. The data was recorded as absorbance relative to the film
base density and analyzed using an Apple microcamputer.
MPE*Fe (TT) Cleaves DNA with Lower Sequenc Seiicity than DNase I
MPE Fe(II) cleavage of a 381 base pair DNA restriction fragment
labeled at either the 3' or 5' end with 32P affords a relatively uniform DNA
cleavage pattern on a Maxam-Gilbert sequencing gel. (Figures 3 and 4, lane 2)
Densitametry reveals that the variation in average peak height is modest
throughout the entire scan. Although MPE-Fe(II) cleavage of DNA is relatively
non-specific, the reagent is not sequence neutral. DNase I exhibits a higher
sequence specificity than MPE-Fe(II) as seen in both autoradiograms (Figures 3
and 4, lane 3). DNase I cleavage specificity over the span of a few base
pairs can range one order of magnitude in absorbance intensity in densitameter
scans.
Footpinting at Low~Drug Bind"n Densities
Actinomycin D, chromomycin A3 and distamycin A were equilibrated at
low concentrations with the 381 base pair DNA restriction fragment (0.06
drug/DNA base pairs) followed by partial cleavage with MPE-Fe(II) or DNase I.
The autoradiograms of the DNA cleavage inhibition patterns are shown in
Figures 3 and 4. Fram densitometric analyses, the footprints on 70 base pairs
of the 381 bp DNA fragment are shown in Figure 5. For actinomycin D, DNase I
affords a footprint 6 to 12 base pairs in size while MPE-Fe(II) does not
detect a strongly bound drug site. For chromonycin, DNase I reports three
footprints while MPE-Fe(II) reports five which are smaller in size. For
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Figure 3: Autoradiogram of 3' end labeled 381 DNA fragment: Lane 1 contains
the intact DNA. Lane 16 is the Maxam-Gilbert G lane. All other even-numbered
lanes (2,4,6,8,10,12,14) contained 10 mM Tris pH 7.4, 50 mM NaCl, 200 PM base
pairs DNA, 4 mM DIT and 10 Mt MPE-Fe(II) with final concentrations in a 10 pl
reaction volume. All other odd-numbered lanes (3,5,7,9,11,13,15) contained 10
mM Tris pH 7.9, 10 mM KC1, 10 mM MgCl2, 5 mM CaC12, 200 PM base pairs DNA, 0.1
mM DTT, and 50 pg DNase I final concentrations in a 10 p1 reaction volume.
Inhibiting drugs in these reactions were: lanes 4 and 5, 12.5 PM actinomycin
D; lanes 6 and 7, 50 PM actinomycin D; lanes 8 and 9, 12.5 pM chrcmcmycin A3
and 25 PM MgC12; lanes 10 and 11, 50 pM chrcmnmycin A3 and 100 PM MgC12; lanes
12 and 13, 12.5 pTM distamycin A; lanes 14 and 15, 50 pM distamycin A.
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Figure 4: Autoradiogram of 5' end labeled 381 DNA fragment: Lane 1 contains
the intact DNA. Lane 16 is the Maxam-Gilbert G lane. All other even-numbered
lanes (2,4,6,8,10,12,14) contained 10 mM Tris pH 7.4, 50 mM NaCl, 400 pM base
pairs DNA, 4 mM DIT and 10 PM MPE-Fe(II) with final concentrations in a 10 p1
reaction volume. All other odd-numbered lanes (3,5,7,9,11,13,15) contained 10
mM Tris pH 7.9, 10 mM KC1, 10 mM MgCl2, 5 mM CaC12, 400 pM base pairs DNA, 0.1
mM DIT, and 50 pg DNase I final concentrations in a 10 p1 reaction volume.
Inhibiting drugs in these reactions were: lanes 4 and 5, 25 pM actinomycin D;
lanes 6 and 7, 100 pM actinasycin D; lanes 8 and 9, 25 pM chrcmanycin A3 and
50 PM MgC12; lanes 10 and 11, 100 pM chrcmanycin A3 and 200 PM MgC12; lanes 12
and 13, 25 pM distauycin A; lanes 14 and 15, 100 pM distamycin A.
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Actinomycin D
5CGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGT
340- 3W0 300' 2W0'3'GCGCATCAGCTATCACCGAGGTTCATCGCTTCGCTCGTCCTGACCCGCCGCCGGTTTCGCCAGCCTGTCA
Actinomycin D
5'CGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGC6AGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGT
340- 3W- 300- 260-3GCGCATCAGCTATCACCGAGGTTCATCGCTTCGCTCGTCCTGACCCGCCGCCGGTTTCGCCAGCCTGTCA
_ - - -._
Chromomycin A3
5CGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGT
340- 32D- 300- 260-3GCGCATCAGCTATCACCGAGGTTCATCGCTTCGCTCGTCCTGACCCGCCGCCGGT'TTCGCCAGCCTGTCA
Chromomycin A3
5CGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCBA6CABGACTSGCBCGGCBCCAAABC6GTC6GACAGT
340- 330- 300 2603GCGCATCAGCTATCACCGAGGTTCATCGCTTC6CTC6TCCT6ACCC6CC6CC¢6TTTCGCCAGCCTGTCA
_
~-
_ _
Distamycin A
5CGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGT
340- 360 300 2603'GCGCATCAGCTATCACCGAGGTTCATCGCTTCGCTC6TCCTGACCCGCCGCCGGTTTCGCCAGCCTGTCA
Distomycin A
- -
5'CGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTC6GACAGT340- 32- 300 20-3GCGCATCAGCTATCACCGAGGTTCATCGCTTCGCTCGTCCTGACCCGCCGCCGGTTTCGCCAGCCTGTCA
Figure 5: MPE-Fe(II) and DNase I footprints on both strands of 70 nucleotides
of the 381 bp DM fragmnt corre ing to bottan to middle of autoradiograms
in Figs. 3 and 4. The DNase I footprints are shown as light and dark bars due
to partial and complete cleavage inhibition, respectively. The MPE-Fe(II)
footprints are shown as histograms. Bottan strand footprints are fran Figure
3. Top strand footprints are fran Figure 4. ¶o binding densities are shown
for each inhibiting drug; top is 0.06 drug/base pair, bottom is 0.25 drug/base
pair.
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Figure 6: Autoradiogram of 2.= repressor-operator footprint. Lane 1
contained the intact 117 bp DNA fragment. Lane 6 is the Maxam-Gilbert G lane.
Lanes 2-5 contained 10 mMsTris Ph 7.4,50 mM NaCl, 100 pM base pairsD.A, 4 sf
DTT,, and 10 UM MPE*Fe (II) at final concentration in 10 11] reaction volumes.
Lanes 7-10 contained 10 mf4 Na cacodylate pH 8 , 10 sf4 MgC12 5 sf4 Cacl2,, 10 'PM
base pairs EM, 0.1 sf4 DTi', and 10 pg DNase I final concentrations in 100 pli
reaction volumes. The amount of 2.= repressor present in each reaction was
none (lanes 2 and 10), 0.75 pig (lanes 3 and 9)j, 3 pig (lanes 4 and 8)j, and
15 pg (lanes Sand 7).
distasnycin A,, the single binding site detected by DNase I is 9 base pairs in
size whereas theogEaFe(II) footprint is 5 base pairs in size (Figure 8).
Footpinting at High Drug Binding Dnities
The three drugs were allowed to equilibrate with the sameDAi
restriction fragment at higher concentrations (0.25 drug/DM base pairs)
followed by partial cleavage with MPEFe(II) or DNase I. The autoradiograme
of the corresponding footprints are shown in Figures 3 and 4. Fram
densitoLetric analyses, the footprints o 70 base pairs of the 381 bp DNA
fraen are showmn in Figure 5. For actinomycin Di, MPE-Fe(II) partial
cleavage reveals six footprints 2-5 base pairs in size. DNase I partial
cleavage exhibits three footprints, two 5-6 base pairs and one 36 base pairs
in size whichec_assses three of the discreteMPEeFe(II) footprints. For
chromcwcinA3,b MPE*Fe(II) partial cleavage reveals seven footprints. DNase I
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0.75 ,.g lac repressor
5' ATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAG 3'
60- 80-
3' TATTACACACCTTAACACTCGCCTATTGTTAAAGTGTGTC 5'
Figure 7: MPE-Fe(II) and DNase I footprint of ia= repressor (7.5 ig/ml) on 40
nucleotides of the 117 bp DNA fragment (Figure 6, lanes 3 and 9). The DNase I
footprints are shown as a dark bar. The MPE-Fe(II) footprints are shown as
histograms.
reports four footprints, one of which is 36 base pairs in size. For
distamycin, MPE*Fe(II) partial cleavage reveals four discrete footprints 5-6
base pairs in size. DNase I partial cleavage exhibits three footprints, one 7
base pairs and two 16 and 25 base pairs in size, respectively.(Figure 8)
Actinomycin
5CGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGT
SGCGCAtCAGCTATCACCGAGGTTCATCGCTTCGCTCGTCCTGACCCGCCGCCGGTTTCGCCAGCCTGTCA
5'CG GTAGTCGATAGTGGCffNqAAGTAGCGAAGCGA ,4GGACTGGCf 1CCGGCCAAWGC GGT CAGT3GCJCATCAGCTATCACCG G TTCATCGCTTCGCTgCCTGAC C CAGGTTGTCA
_________GW L
Chromomycin
5'C GTAGTCGATAGTG"TCCAAGTAGCGAAGCGAGCAGGACTGG C GCP-wCA G GGTCGGACAGT3'GC
-ATCAGCTATCAC G AGGTTCATCGCTTCGCTCGTCCTGACCPGgCGG TTTSCCAGCCTGTCA
- 5'C jGTAGTCGATAGTG"T CCAAGTAGCGAA ABC BCTB C B A B6BTCGGACAGT3'GK_CATCAGCTATCACjAGGTTCATCGCTTECTCB C ACCT:BC7iEVSTT1CRCCAGCCTGTCA
Distamycin
5'CGCGTAGTCGATAGTGGCTCCKYAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGT3'GCGCATCAGCTATCACCGAG GICATJCGCTTCGCTCGTCCTGACCCGCCGCCGGTTTCGCCAGCCTGTCA
5sCGCGTGFCGtGCTCC|AATA|GCGAAGCGAGCAGGACTGGGCGGCGGCAAA GGTCGGAC T
3AGCGC CACA A AT GCTTCGCTCGTCCTGACCCGCCGCCGLGTTTCGCCACCCTC
Figure 8: Illustration of MPE-Fe(II) footprints (boxes) and DNase I footprints
(brackets) fron Figure 5.
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MS.e(II) Footprint of the Jac Reessor
For canparison the characterized J.= repressor-operator system was
examined by both footprinting methods.(Figure 6) A 3' 32p end labeled 117
base pair DNA restriction fragment containing one copy of the UV-5 1ac operon
mutation, preequilibrated with several concentrations of the 2= repressor
protein (0.75 to 15 ig), were subjected to either MPE-Fe(II) or DNase I
partial cleavage. Identical footprinting patterns are observed by both
methods at the low Jla repressor binding levels (0.75 and 3 pg) as seen in
Figure 7. At 15 pg Jla repressor DNase I cleavage is sufficiently inhibited
such that a discrete footprint is no longer visible (Figure 6, lane 7).
MPE-Fe(II) footprints la repressor throughout the concentration range tested.
DISCISSION
There are significant differences between MPE-Fe(II) and DNase I as
DNA cleaving agents for determining the sequence specific binding of small
molecules to native DNA. In the case of actincmycin at low binding density,
DNase I footprinting appears more sensitive. The sensitivity of DNase I for
weakly bound sites may be due to differences in the binding affinities of
DNase I and MPE-Fe(II) to DM^. However, MPE Fe(II) footprinting appears more
accurate in determining the actual size and location of binding sites for
small molecules on DNA, especially in cases where several drugs are closely
spaced on DN. 'This is implied by the consistently smaller and discrete
footprints observed with MPE*Fe(II) cleavage which more closely resemble the
expected locations and binding site sizes for actinanycin D, chrmancycin A3
and distanycin A fran equilibrium binding studies.(3) Direct evidence
supporting this is obtained fran DNA cleavage patterns generated fram cleavage
of 32p labeled DNA restriction fragments with distamycin-EUrA-Fe(II) and EDTA-
distamycin-Fe(II) which indicate that the binding site size of distamycin is
4 base pairs.(26) In addition, MPE-Fe(II) footprinting of distamycin on these
same DNA fragments reveals DNk cleavage inhibition patterns at identical sites
of similar size. (27) With multiple bound drugs that are closely spaced on
DNA, DNase I footprinting affords large regions of cleavage inhibition making
accurate site and size determinations impossible.
The difference in the size of the footprints for drug binding sites
generated by DNase I and MPE-Fe(II) may be a reflection of the differences in
size of the DNA cleaving agents. MPE, an intercalator, is significantly
smaller than DNase I, a high molecular weight protein. One might imagine that
the catalytic site on the enzyme might not be accessible to the unprotected
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base pairs imrediately flanking the bound drug in the minor groove of DMI
affording a slightly larger footprint. MPE-Fe(II) presumably binds the
unprotected DMX sites by intercalation. The cleavage event, an oxidative
degradation of the deoxyribose ring, appears to be mediated by a localized
concentration of a short lived diffusible active oxygen species near the DN4
backbone.(10,26,28) Therefore, MPE-Fe(II) footprints might simply represent
regions of the DMA where a bound molecule directly inhibits intercalation by
MPE. Assignment of the drug binding site size frcn MPE-Fe(II) footprinting is
based on a model where the DM cleavage inhibition pattern is shifted 1-2 base
pairs on the 3' side and 1 base pair underprotected on the 5' side of the
DA. (8,9)
DNase I is known to be sensitive to DNA structure. (29) An alternative
explanation for the larger binding-site sizes for DNase I footprinting is that
DNase I cleavage is inhibited (or enhanced) by altered DNA structure.(11) If
this is true and assuming that MPE-Fe(II) footprints represent regions of
direct inhibition, the coupled uses of MPE'Fe(II) and DNase I footprinting may
provide a method for determining the extent and sequence dependence of altered
DNl structure induced by small molecules at specific sites on DNM.
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